Aubagio

Natalizumab ( Tysabri ), a humanized monoclonal antibody, was approved by the Food and Drug Administration ( FDA ) in...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more...


Teriflunomide ( Aubagio ) is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis. Researchers have assessed the...


Teriflunomide ( Aubagio ) is an oral disease-modifying therapy approved for treatment of relapsing or relapsing–remitting multiple sclerosis. Researchers aimed...


The FDA ( Food and Drug Administration ) has approved the inclusion of efficacy and safety data from the TOWER...


European Commission ( EU ) has granted marketing authorization for Aubagio ( Teriflunomide ) 14 mg, a once-daily, oral therapy...


Disease-modifying therapies ( DMTs ) for multiple sclerosis aim to specifically reduce inflammation in relapsing multiple sclerosis and promote neuroprotection...


Results from the TOWER ( Teriflunomide Oral in people With relapsing remitting multiplE scleRosis ) trial that assessed the efficacy...